27 Spam-Free Article(s) Found
https://www.zacks.com/stock/news/2193796/alterity-athe-up-on-preclinical-parkinson-s-treatment-data?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2193796
Dec 05, 2023 - Data from a preclinical study shows that treatment with Alterity's (ATHE) lead candidate improved motor performance and general function in monkeys with experimentally-induced Parkinson's disease.
zc:4895263113134935734
0
https://www.zacks.com/stock/news/2193794/crispr-crsp-to-focus-on-next-generation-car-t-pipeline?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2193794
Dec 05, 2023 - Based on early data from ongoing clinical studies, CRISPR (CRSP) has decided to focus on the development of its next-generation CAR T pipeline and discontinue its first-generation CAR T candidates.
zc:7993331517159655985
0
https://www.zacks.com/stock/news/2193518/vanda-vnda-rises-as-fda-accepts-nda-for-gastroparesis-drug?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2193518
Dec 05, 2023 - The FDA accepts Vanda's (VNDA) new drug application ("NDA") for tradipitant for treating the symptoms of gastroparesis. The company's shares rise in after-hours trading.
zc:2820871868858812633
0
https://www.zacks.com/stock/news/2193345/is-it-a-good-idea-to-invest-in-ac-immune-aciu-stock-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2193345
Dec 05, 2023 - Here, we discuss some reasons why investing in AC Immune (ACIU) stock now may turn out to be a prudent move.
zc:-2496330855438267457
0
https://www.zacks.com/stock/news/2193043/apellis-apls-rides-on-syfovre-to-fuel-growth-amid-rivalry?cid=CS-ZC-FT-analyst_blog|zer_report_update-2193043
Dec 04, 2023 - Apellis' (APLS) marketed products, Syfovre and Empaveli, continue to remain the growth drivers since launch. However, stiff competition in the target markets remains a woe.
zc:7679748898766635001
0
https://www.zacks.com/stock/news/2192314/astrazeneca-azn-to-discontinue-two-studies-on-lokelma?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2192314
Dec 01, 2023 - Owing to increased enrollment timelines and low event rates, AstraZeneca (AZN) plans to stop the STABILIZE-CKD and DIALIZE-Outcomes phase III evidence studies for the hyperkalemia drug Lokelma.
zc:7666228982501549482
0
https://www.zacks.com/stock/news/2192301/annovis-bio-anvs-stock-surges-38-in-a-month-here-s-why?cid=CS-ZC-FT-analyst_blog|price_surge_/_plunge-2192301
Dec 01, 2023 - Annovis' (ANVS) shares surge on the successful development of its lead candidate in Alzheimer's disease.
zc:-4186102150951624207
0